Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.

Also called NCT06921616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 396 participants (planned count) (from the registry)
Sponsor
Yong Jiang (from the registry)
Registry
  • NCT NCT06921616
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06921616. Randomized; triple masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
Acronym
HEMS
Condition
Stroke
Condition
Intracerebral Hemorrhage Lobar
Condition
Methylprednisolone
Condition
Surgery
Intervention (Procedure)
Simple neuroendoscopic hematoma evacuation
Intervention (Combination product)
Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
Lead sponsor
Yong Jiang (class: other)

Record details

Record id
cardio:ct-nct06921616
Content hash
6fc750e45ab47626ea16595aae4690593a1e3986ecd945020aacee5ebc60f9e3